| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza A virus | 12 | 2025 | 122 | 3.180 |
Why?
|
| Influenza, Human | 16 | 2025 | 213 | 3.160 |
Why?
|
| Diabetes Mellitus, Type 1 | 8 | 2025 | 631 | 2.700 |
Why?
|
| Antiviral Agents | 15 | 2025 | 332 | 2.560 |
Why?
|
| Interferon Type I | 9 | 2025 | 198 | 1.980 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 10 | 2025 | 87 | 1.830 |
Why?
|
| Islets of Langerhans | 7 | 2025 | 286 | 1.740 |
Why?
|
| Drug Resistance, Viral | 7 | 2022 | 167 | 1.350 |
Why?
|
| Oseltamivir | 6 | 2022 | 37 | 1.250 |
Why?
|
| Immunity, Innate | 9 | 2021 | 829 | 1.210 |
Why?
|
| Adenosine Monophosphate | 4 | 2024 | 30 | 1.080 |
Why?
|
| Alanine | 4 | 2024 | 49 | 1.080 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 6 | 2022 | 47 | 1.040 |
Why?
|
| Dendritic Cells | 9 | 2015 | 534 | 1.000 |
Why?
|
| Macrophages | 6 | 2021 | 1042 | 0.990 |
Why?
|
| Receptor, Interferon alpha-beta | 4 | 2025 | 54 | 0.960 |
Why?
|
| Toll-Like Receptor 7 | 5 | 2019 | 104 | 0.920 |
Why?
|
| Janus Kinase Inhibitors | 2 | 2025 | 20 | 0.900 |
Why?
|
| Cytokines | 13 | 2025 | 965 | 0.870 |
Why?
|
| Neuraminidase | 4 | 2022 | 47 | 0.850 |
Why?
|
| Antibodies, Viral | 7 | 2025 | 329 | 0.840 |
Why?
|
| Enterovirus B, Human | 4 | 2020 | 17 | 0.840 |
Why?
|
| RNA, Viral | 6 | 2024 | 267 | 0.780 |
Why?
|
| Host-Pathogen Interactions | 2 | 2025 | 279 | 0.770 |
Why?
|
| Animals | 45 | 2025 | 21492 | 0.760 |
Why?
|
| Prediabetic State | 1 | 2023 | 54 | 0.720 |
Why?
|
| Autoimmunity | 2 | 2021 | 250 | 0.720 |
Why?
|
| Parvoviridae Infections | 1 | 2021 | 23 | 0.700 |
Why?
|
| Coxsackievirus Infections | 3 | 2020 | 12 | 0.680 |
Why?
|
| Pyrazines | 2 | 2017 | 35 | 0.630 |
Why?
|
| Amides | 2 | 2017 | 61 | 0.620 |
Why?
|
| Humans | 69 | 2025 | 65831 | 0.620 |
Why?
|
| Dogs | 10 | 2019 | 326 | 0.610 |
Why?
|
| Membrane Glycoproteins | 7 | 2019 | 667 | 0.610 |
Why?
|
| Herpesvirus 1, Human | 4 | 2024 | 83 | 0.600 |
Why?
|
| Influenza Vaccines | 3 | 2025 | 100 | 0.590 |
Why?
|
| Rats | 5 | 2025 | 2005 | 0.570 |
Why?
|
| Pyrazoles | 3 | 2025 | 88 | 0.540 |
Why?
|
| Orthomyxoviridae Infections | 2 | 2017 | 63 | 0.530 |
Why?
|
| Interferon-alpha | 4 | 2014 | 101 | 0.530 |
Why?
|
| Toll-Like Receptors | 8 | 2011 | 434 | 0.520 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2017 | 7 | 0.510 |
Why?
|
| Blood Platelets | 3 | 2025 | 108 | 0.500 |
Why?
|
| Herpes Simplex | 4 | 2024 | 49 | 0.500 |
Why?
|
| Mice | 28 | 2024 | 11185 | 0.490 |
Why?
|
| DEAD-box RNA Helicases | 3 | 2014 | 134 | 0.480 |
Why?
|
| Cell Line | 12 | 2021 | 2031 | 0.480 |
Why?
|
| Male | 28 | 2025 | 31403 | 0.480 |
Why?
|
| Biological Evolution | 1 | 2017 | 129 | 0.480 |
Why?
|
| Double-Blind Method | 8 | 2025 | 747 | 0.470 |
Why?
|
| Genome, Viral | 2 | 2015 | 145 | 0.470 |
Why?
|
| Viral Load | 2 | 2024 | 230 | 0.470 |
Why?
|
| Virus Replication | 5 | 2025 | 323 | 0.470 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2025 | 20 | 0.460 |
Why?
|
| Female | 29 | 2025 | 34420 | 0.450 |
Why?
|
| Adult | 20 | 2025 | 17575 | 0.440 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 2019 | 179 | 0.440 |
Why?
|
| Mutation | 5 | 2024 | 2675 | 0.440 |
Why?
|
| Antibodies, Neutralizing | 4 | 2025 | 220 | 0.430 |
Why?
|
| Coronavirus Infections | 3 | 2021 | 206 | 0.430 |
Why?
|
| Toll-Like Receptor 8 | 2 | 2012 | 49 | 0.430 |
Why?
|
| Imidazoles | 3 | 2023 | 82 | 0.420 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 3 | 2025 | 25 | 0.420 |
Why?
|
| Plasmodium falciparum | 1 | 2017 | 262 | 0.420 |
Why?
|
| Metformin | 1 | 2025 | 77 | 0.420 |
Why?
|
| Malaria, Falciparum | 1 | 2017 | 239 | 0.420 |
Why?
|
| Myeloid Differentiation Factor 88 | 3 | 2011 | 203 | 0.410 |
Why?
|
| Rats, Inbred Lew | 2 | 2025 | 106 | 0.410 |
Why?
|
| Evolution, Molecular | 4 | 2018 | 351 | 0.410 |
Why?
|
| Plasma | 2 | 2019 | 39 | 0.400 |
Why?
|
| Hyperglycemia | 1 | 2014 | 109 | 0.400 |
Why?
|
| Neutrophils | 3 | 2021 | 396 | 0.390 |
Why?
|
| Hypoglycemic Agents | 1 | 2025 | 226 | 0.380 |
Why?
|
| Toll-Like Receptor 9 | 2 | 2011 | 207 | 0.380 |
Why?
|
| Viral Proteins | 3 | 2022 | 273 | 0.380 |
Why?
|
| Sialic Acids | 1 | 2013 | 33 | 0.380 |
Why?
|
| Cryptococcus neoformans | 2 | 2011 | 142 | 0.380 |
Why?
|
| Treatment Outcome | 11 | 2025 | 5834 | 0.370 |
Why?
|
| Mice, Knockout | 12 | 2019 | 2168 | 0.370 |
Why?
|
| Signal Transduction | 6 | 2025 | 3170 | 0.350 |
Why?
|
| Receptors, Interleukin-18 | 1 | 2011 | 9 | 0.350 |
Why?
|
| Azetidines | 2 | 2022 | 8 | 0.350 |
Why?
|
| Purines | 2 | 2022 | 43 | 0.340 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2011 | 64 | 0.340 |
Why?
|
| Mycobacterium tuberculosis | 3 | 2020 | 424 | 0.340 |
Why?
|
| Polysaccharides | 1 | 2013 | 155 | 0.340 |
Why?
|
| Middle Aged | 17 | 2025 | 18498 | 0.330 |
Why?
|
| Aspergillosis | 3 | 2023 | 35 | 0.330 |
Why?
|
| Cells, Cultured | 9 | 2020 | 2194 | 0.320 |
Why?
|
| Sulfonamides | 2 | 2022 | 135 | 0.320 |
Why?
|
| Gene Expression Regulation | 6 | 2021 | 1635 | 0.320 |
Why?
|
| Gene Editing | 2 | 2025 | 331 | 0.320 |
Why?
|
| Central Nervous System | 1 | 2011 | 205 | 0.300 |
Why?
|
| Mice, Inbred C57BL | 13 | 2019 | 3506 | 0.300 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2025 | 256 | 0.300 |
Why?
|
| Parvovirus | 2 | 2021 | 25 | 0.300 |
Why?
|
| Virus Diseases | 2 | 2007 | 118 | 0.300 |
Why?
|
| Receptors, Cell Surface | 4 | 2008 | 432 | 0.300 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 220 | 0.290 |
Why?
|
| Disease Models, Animal | 5 | 2025 | 2329 | 0.290 |
Why?
|
| Oligodeoxyribonucleotides | 3 | 2008 | 242 | 0.290 |
Why?
|
| Receptors, Pattern Recognition | 2 | 2025 | 36 | 0.280 |
Why?
|
| Biomarkers | 1 | 2024 | 1502 | 0.280 |
Why?
|
| Inflammation | 4 | 2023 | 1198 | 0.270 |
Why?
|
| A549 Cells | 2 | 2025 | 39 | 0.260 |
Why?
|
| Blood Component Transfusion | 1 | 2017 | 11 | 0.260 |
Why?
|
| CRISPR-Cas Systems | 2 | 2025 | 369 | 0.260 |
Why?
|
| Mutation Rate | 2 | 2017 | 24 | 0.250 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 441 | 0.250 |
Why?
|
| Cardiovirus Infections | 2 | 2019 | 14 | 0.250 |
Why?
|
| Encephalomyocarditis virus | 2 | 2019 | 15 | 0.250 |
Why?
|
| Plasma Cells | 1 | 2007 | 52 | 0.250 |
Why?
|
| Monocytes | 2 | 2005 | 362 | 0.240 |
Why?
|
| Insulin-Secreting Cells | 4 | 2025 | 195 | 0.240 |
Why?
|
| Poly I-C | 2 | 2025 | 76 | 0.240 |
Why?
|
| Madin Darby Canine Kidney Cells | 4 | 2019 | 22 | 0.240 |
Why?
|
| Dengue Virus | 1 | 2006 | 101 | 0.240 |
Why?
|
| Herpesvirus 3, Human | 1 | 2005 | 9 | 0.230 |
Why?
|
| Genetics, Population | 2 | 2017 | 46 | 0.230 |
Why?
|
| Aspergillus fumigatus | 4 | 2023 | 38 | 0.230 |
Why?
|
| Herpes Zoster | 1 | 2005 | 22 | 0.230 |
Why?
|
| Endosomes | 1 | 2006 | 180 | 0.230 |
Why?
|
| Listeria monocytogenes | 1 | 2005 | 33 | 0.230 |
Why?
|
| Salmonella enterica | 1 | 2005 | 26 | 0.220 |
Why?
|
| Aged | 11 | 2025 | 15145 | 0.220 |
Why?
|
| Adenosine Deaminase | 1 | 2025 | 22 | 0.220 |
Why?
|
| Leukocytes | 1 | 2025 | 110 | 0.220 |
Why?
|
| RNA | 2 | 2023 | 427 | 0.210 |
Why?
|
| Sulfides | 1 | 2024 | 22 | 0.210 |
Why?
|
| Acetates | 1 | 2024 | 30 | 0.210 |
Why?
|
| Deoxyribonucleotides | 1 | 2024 | 13 | 0.210 |
Why?
|
| Nitriles | 1 | 2025 | 82 | 0.210 |
Why?
|
| Antitubercular Agents | 1 | 2005 | 85 | 0.210 |
Why?
|
| In Vitro Techniques | 3 | 2013 | 491 | 0.210 |
Why?
|
| Quinolines | 1 | 2024 | 47 | 0.210 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 297 | 0.210 |
Why?
|
| Organoids | 1 | 2024 | 44 | 0.210 |
Why?
|
| Cyclopropanes | 1 | 2024 | 57 | 0.210 |
Why?
|
| Apoptosis | 2 | 2021 | 1100 | 0.210 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2024 | 39 | 0.210 |
Why?
|
| Immunocompromised Host | 1 | 2025 | 104 | 0.210 |
Why?
|
| Pyrimidines | 1 | 2025 | 144 | 0.210 |
Why?
|
| Selection, Genetic | 2 | 2015 | 90 | 0.200 |
Why?
|
| Administration, Intravenous | 2 | 2020 | 78 | 0.200 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2025 | 100 | 0.200 |
Why?
|
| Invasive Pulmonary Aspergillosis | 1 | 2023 | 5 | 0.200 |
Why?
|
| Serine Endopeptidases | 2 | 2021 | 125 | 0.200 |
Why?
|
| Adolescent | 5 | 2025 | 6367 | 0.200 |
Why?
|
| Pulmonary Aspergillosis | 1 | 2023 | 10 | 0.200 |
Why?
|
| Liposomes | 2 | 2015 | 118 | 0.200 |
Why?
|
| Oxygen | 2 | 2022 | 323 | 0.200 |
Why?
|
| Antigen Presentation | 1 | 2025 | 239 | 0.200 |
Why?
|
| Thrombosis | 1 | 2025 | 207 | 0.190 |
Why?
|
| Antigen-Antibody Complex | 3 | 2014 | 52 | 0.190 |
Why?
|
| Trans-Activators | 2 | 2020 | 321 | 0.190 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 799 | 0.180 |
Why?
|
| Models, Molecular | 4 | 2019 | 1161 | 0.180 |
Why?
|
| Recombinant Proteins | 4 | 2017 | 710 | 0.180 |
Why?
|
| Nasal Lavage | 1 | 2021 | 2 | 0.180 |
Why?
|
| Rats, Transgenic | 1 | 2021 | 7 | 0.180 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 52 | 0.180 |
Why?
|
| Interferon beta-1a | 1 | 2021 | 9 | 0.180 |
Why?
|
| Chemotaxis | 1 | 2021 | 51 | 0.170 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2021 | 28 | 0.170 |
Why?
|
| Respiratory Mucosa | 1 | 2021 | 51 | 0.170 |
Why?
|
| RNA-Binding Proteins | 1 | 2025 | 446 | 0.170 |
Why?
|
| Dexamethasone | 1 | 2022 | 214 | 0.160 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2020 | 16 | 0.160 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2021 | 179 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 449 | 0.160 |
Why?
|
| Bursa, Synovial | 1 | 2000 | 1 | 0.160 |
Why?
|
| Sporotrichosis | 1 | 2000 | 2 | 0.160 |
Why?
|
| Sporothrix | 1 | 2000 | 3 | 0.160 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2021 | 207 | 0.160 |
Why?
|
| Transcriptome | 2 | 2024 | 408 | 0.160 |
Why?
|
| Nasal Mucosa | 1 | 2020 | 17 | 0.160 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2020 | 8 | 0.160 |
Why?
|
| Goblet Cells | 1 | 2020 | 10 | 0.160 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 220 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 542 | 0.160 |
Why?
|
| Young Adult | 5 | 2025 | 4882 | 0.160 |
Why?
|
| Bursitis | 1 | 2000 | 18 | 0.160 |
Why?
|
| Enterocytes | 1 | 2020 | 25 | 0.160 |
Why?
|
| Sequence Analysis, RNA | 2 | 2019 | 182 | 0.160 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 45 | 0.160 |
Why?
|
| Endocrine Cells | 1 | 2019 | 10 | 0.150 |
Why?
|
| Respiration, Artificial | 3 | 2020 | 301 | 0.150 |
Why?
|
| Epitopes | 1 | 2021 | 291 | 0.150 |
Why?
|
| Up-Regulation | 4 | 2020 | 377 | 0.150 |
Why?
|
| Pandemics | 4 | 2023 | 692 | 0.150 |
Why?
|
| Capsid Proteins | 1 | 2020 | 107 | 0.150 |
Why?
|
| Immunization, Passive | 1 | 2019 | 97 | 0.150 |
Why?
|
| Platelet Activation | 1 | 2019 | 31 | 0.150 |
Why?
|
| Reverse Genetics | 1 | 2019 | 11 | 0.140 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 277 | 0.140 |
Why?
|
| Disease Resistance | 1 | 2019 | 27 | 0.140 |
Why?
|
| ADAM Proteins | 1 | 2019 | 36 | 0.140 |
Why?
|
| Neutralization Tests | 1 | 2019 | 126 | 0.140 |
Why?
|
| Extracellular Traps | 2 | 2019 | 45 | 0.140 |
Why?
|
| Lectins, C-Type | 3 | 2015 | 80 | 0.140 |
Why?
|
| Repressor Proteins | 1 | 2020 | 351 | 0.140 |
Why?
|
| Silent Mutation | 1 | 2018 | 5 | 0.140 |
Why?
|
| High-Throughput Screening Assays | 2 | 2021 | 80 | 0.140 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2017 | 35 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 420 | 0.130 |
Why?
|
| Knee Joint | 1 | 2000 | 312 | 0.130 |
Why?
|
| Genetic Fitness | 1 | 2018 | 35 | 0.130 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2017 | 60 | 0.130 |
Why?
|
| Enzyme Inhibitors | 2 | 2016 | 372 | 0.130 |
Why?
|
| Alzheimer Disease | 1 | 2024 | 773 | 0.130 |
Why?
|
| Quinidine | 1 | 2017 | 2 | 0.130 |
Why?
|
| Gravidity | 1 | 2017 | 11 | 0.130 |
Why?
|
| Chemoprevention | 1 | 2017 | 26 | 0.130 |
Why?
|
| Chloroquine | 1 | 2017 | 56 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 679 | 0.130 |
Why?
|
| Species Specificity | 3 | 2007 | 344 | 0.120 |
Why?
|
| Vero Cells | 2 | 2015 | 81 | 0.120 |
Why?
|
| Anti-Retroviral Agents | 1 | 2016 | 76 | 0.120 |
Why?
|
| Viruses | 2 | 2007 | 82 | 0.120 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2020 | 61 | 0.120 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2025 | 9 | 0.120 |
Why?
|
| Vaccines, Inactivated | 1 | 2025 | 14 | 0.120 |
Why?
|
| Brain | 1 | 2024 | 1672 | 0.120 |
Why?
|
| Antimalarials | 1 | 2017 | 131 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 211 | 0.120 |
Why?
|
| RNA Caps | 1 | 2015 | 17 | 0.110 |
Why?
|
| Hemagglutination | 2 | 2013 | 4 | 0.110 |
Why?
|
| Healthy Volunteers | 1 | 2025 | 75 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2020 | 738 | 0.110 |
Why?
|
| Fever | 1 | 2025 | 67 | 0.110 |
Why?
|
| Vaccines, Synthetic | 1 | 2025 | 80 | 0.110 |
Why?
|
| Down-Regulation | 2 | 2014 | 326 | 0.110 |
Why?
|
| Reassortant Viruses | 1 | 2015 | 10 | 0.110 |
Why?
|
| Parainfluenza Virus 3, Human | 1 | 2015 | 2 | 0.110 |
Why?
|
| Recurrence | 1 | 2017 | 665 | 0.110 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2015 | 18 | 0.110 |
Why?
|
| Lung | 4 | 2023 | 969 | 0.110 |
Why?
|
| Simplexvirus | 1 | 2015 | 26 | 0.110 |
Why?
|
| Membrane Proteins | 2 | 2019 | 926 | 0.110 |
Why?
|
| Interferon-gamma | 3 | 2007 | 576 | 0.100 |
Why?
|
| Betacoronavirus | 2 | 2020 | 182 | 0.100 |
Why?
|
| NF-kappa B | 2 | 2006 | 436 | 0.100 |
Why?
|
| Interferon-Induced Helicase, IFIH1 | 2 | 2014 | 16 | 0.100 |
Why?
|
| Plasmodium berghei | 1 | 2014 | 21 | 0.100 |
Why?
|
| Hemostatics | 1 | 2014 | 27 | 0.100 |
Why?
|
| Interferon-beta | 1 | 2014 | 79 | 0.100 |
Why?
|
| Malaria, Cerebral | 1 | 2014 | 24 | 0.100 |
Why?
|
| Antigens, Viral | 1 | 2024 | 130 | 0.100 |
Why?
|
| Interleukin-1beta | 2 | 2014 | 274 | 0.100 |
Why?
|
| Viral Plaque Assay | 1 | 2013 | 15 | 0.100 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 52 | 0.100 |
Why?
|
| Respiratory Tract Infections | 2 | 2021 | 90 | 0.100 |
Why?
|
| Receptors, Virus | 2 | 2020 | 73 | 0.100 |
Why?
|
| DNA-Binding Proteins | 2 | 2014 | 1226 | 0.100 |
Why?
|
| Ribonuclease III | 1 | 2013 | 86 | 0.100 |
Why?
|
| Bone Marrow Cells | 1 | 2014 | 237 | 0.100 |
Why?
|
| Chitosan | 1 | 2014 | 89 | 0.100 |
Why?
|
| Rous sarcoma virus | 1 | 2013 | 3 | 0.100 |
Why?
|
| Sendai virus | 1 | 2013 | 11 | 0.100 |
Why?
|
| Outpatients | 2 | 2024 | 143 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 95 | 0.090 |
Why?
|
| Dihydrotestosterone | 1 | 2012 | 21 | 0.090 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 229 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2012 | 605 | 0.090 |
Why?
|
| Interleukin-1alpha | 1 | 2011 | 25 | 0.090 |
Why?
|
| Vibrio cholerae | 1 | 2011 | 18 | 0.090 |
Why?
|
| Th1 Cells | 1 | 2011 | 171 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2014 | 565 | 0.080 |
Why?
|
| Toll-Like Receptor 2 | 3 | 2005 | 219 | 0.080 |
Why?
|
| Receptors, Complement | 1 | 2010 | 15 | 0.080 |
Why?
|
| Adjuvants, Immunologic | 1 | 2011 | 238 | 0.080 |
Why?
|
| Epithelial Cells | 1 | 2013 | 414 | 0.080 |
Why?
|
| Erythrocyte Membrane | 1 | 2010 | 25 | 0.080 |
Why?
|
| Ligands | 2 | 2008 | 414 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2011 | 642 | 0.080 |
Why?
|
| Pneumococcal Infections | 1 | 2010 | 39 | 0.080 |
Why?
|
| Base Sequence | 3 | 2015 | 1332 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2019 | 3339 | 0.080 |
Why?
|
| Pregnancy | 1 | 2017 | 2401 | 0.080 |
Why?
|
| Transplantation, Heterologous | 2 | 2020 | 241 | 0.080 |
Why?
|
| Interleukin-6 | 3 | 2005 | 324 | 0.080 |
Why?
|
| Interleukin-8 | 2 | 2006 | 96 | 0.070 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 66 | 0.070 |
Why?
|
| Sex Factors | 1 | 2012 | 995 | 0.070 |
Why?
|
| Autoantigens | 2 | 2025 | 140 | 0.070 |
Why?
|
| Drosophila melanogaster | 1 | 2013 | 563 | 0.070 |
Why?
|
| beta-Glucans | 1 | 2009 | 51 | 0.070 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 625 | 0.070 |
Why?
|
| Virulence | 2 | 2007 | 199 | 0.070 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2009 | 48 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 1 | 2009 | 95 | 0.070 |
Why?
|
| Neutrophil Activation | 1 | 2008 | 23 | 0.070 |
Why?
|
| Adenoviridae | 1 | 2009 | 132 | 0.070 |
Why?
|
| Binding Sites | 3 | 2017 | 922 | 0.070 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 74 | 0.070 |
Why?
|
| Macrolides | 1 | 2008 | 38 | 0.070 |
Why?
|
| Erythrocytes | 1 | 2009 | 147 | 0.070 |
Why?
|
| DNA, Fungal | 1 | 2008 | 58 | 0.070 |
Why?
|
| Mice, Transgenic | 3 | 2020 | 1292 | 0.070 |
Why?
|
| RNA, Small Interfering | 2 | 2023 | 993 | 0.070 |
Why?
|
| Virus Internalization | 1 | 2008 | 91 | 0.070 |
Why?
|
| Chemokines | 2 | 2008 | 99 | 0.060 |
Why?
|
| Vesicular stomatitis Indiana virus | 1 | 2007 | 16 | 0.060 |
Why?
|
| Rhabdoviridae Infections | 1 | 2007 | 6 | 0.060 |
Why?
|
| Infant | 1 | 2012 | 1718 | 0.060 |
Why?
|
| Receptors, Fc | 1 | 2007 | 25 | 0.060 |
Why?
|
| CpG Islands | 1 | 2008 | 219 | 0.060 |
Why?
|
| Virus Activation | 1 | 2006 | 23 | 0.060 |
Why?
|
| Risk Factors | 1 | 2017 | 5476 | 0.060 |
Why?
|
| Caenorhabditis elegans | 1 | 2013 | 709 | 0.060 |
Why?
|
| Time Factors | 2 | 2020 | 3777 | 0.060 |
Why?
|
| Viral Fusion Proteins | 1 | 2006 | 54 | 0.060 |
Why?
|
| Proteins | 1 | 2011 | 764 | 0.060 |
Why?
|
| Hospitalization | 2 | 2024 | 1404 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2006 | 465 | 0.060 |
Why?
|
| Leukotriene Antagonists | 1 | 2024 | 8 | 0.050 |
Why?
|
| Moloney murine leukemia virus | 1 | 2024 | 17 | 0.050 |
Why?
|
| T-Lymphocytes | 2 | 2025 | 1012 | 0.050 |
Why?
|
| Encephalitis, Viral | 1 | 2004 | 5 | 0.050 |
Why?
|
| Fluvoxamine | 1 | 2023 | 2 | 0.050 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2009 | 573 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1146 | 0.050 |
Why?
|
| Respiratory Burst | 1 | 2003 | 21 | 0.050 |
Why?
|
| STAT1 Transcription Factor | 1 | 2003 | 35 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2005 | 248 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2015 | 1583 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2005 | 664 | 0.050 |
Why?
|
| NADPH Oxidases | 1 | 2003 | 69 | 0.050 |
Why?
|
| Ribosomal Proteins | 1 | 2003 | 42 | 0.050 |
Why?
|
| Sulfoxides | 1 | 2023 | 16 | 0.050 |
Why?
|
| Length of Stay | 1 | 2017 | 828 | 0.050 |
Why?
|
| Abatacept | 1 | 2023 | 67 | 0.050 |
Why?
|
| Hyphae | 2 | 2015 | 17 | 0.050 |
Why?
|
| Infliximab | 1 | 2023 | 50 | 0.050 |
Why?
|
| Stem Cells | 1 | 2024 | 278 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 240 | 0.050 |
Why?
|
| Protein Binding | 2 | 2017 | 1638 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2003 | 224 | 0.050 |
Why?
|
| Electron Microscope Tomography | 1 | 2022 | 18 | 0.040 |
Why?
|
| Singapore | 1 | 2021 | 10 | 0.040 |
Why?
|
| Mexico | 1 | 2021 | 39 | 0.040 |
Why?
|
| Japan | 1 | 2021 | 67 | 0.040 |
Why?
|
| Coronavirus | 1 | 2021 | 14 | 0.040 |
Why?
|
| Peptides | 1 | 2025 | 593 | 0.040 |
Why?
|
| Oligonucleotides | 1 | 2023 | 229 | 0.040 |
Why?
|
| Gene Expression | 2 | 2017 | 856 | 0.040 |
Why?
|
| Bronchi | 1 | 2021 | 86 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2021 | 139 | 0.040 |
Why?
|
| Procainamide | 1 | 2020 | 5 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2021 | 210 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2021 | 195 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2021 | 611 | 0.040 |
Why?
|
| Child | 2 | 2020 | 4651 | 0.040 |
Why?
|
| Equipment Design | 1 | 2021 | 374 | 0.040 |
Why?
|
| Cryoelectron Microscopy | 1 | 2022 | 218 | 0.040 |
Why?
|
| Cloning, Molecular | 2 | 2017 | 387 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 462 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2020 | 263 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 119 | 0.040 |
Why?
|
| Complement C3 | 1 | 2019 | 61 | 0.040 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2019 | 206 | 0.040 |
Why?
|
| Graft Survival | 1 | 2019 | 300 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 97 | 0.040 |
Why?
|
| Polymorphism, Genetic | 2 | 2016 | 199 | 0.040 |
Why?
|
| RNA Folding | 1 | 2018 | 6 | 0.030 |
Why?
|
| Orthomyxoviridae | 1 | 2017 | 29 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2019 | 144 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2017 | 103 | 0.030 |
Why?
|
| Glucose | 1 | 2020 | 478 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2017 | 89 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 238 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2017 | 365 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2017 | 1590 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2017 | 302 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2017 | 261 | 0.030 |
Why?
|
| Zanamivir | 1 | 2016 | 6 | 0.030 |
Why?
|
| Swine | 1 | 2018 | 398 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2017 | 415 | 0.030 |
Why?
|
| Protein Structure, Quaternary | 1 | 2016 | 103 | 0.030 |
Why?
|
| Phylogeny | 1 | 2018 | 399 | 0.030 |
Why?
|
| Hydrogen Bonding | 1 | 2016 | 128 | 0.030 |
Why?
|
| Tuberculosis | 1 | 2020 | 314 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2016 | 252 | 0.030 |
Why?
|
| Thermodynamics | 1 | 2016 | 200 | 0.030 |
Why?
|
| Static Electricity | 1 | 2016 | 172 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 881 | 0.030 |
Why?
|
| Insulin | 1 | 2019 | 697 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2016 | 136 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2018 | 617 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2016 | 345 | 0.030 |
Why?
|
| Genes, Viral | 1 | 2015 | 57 | 0.030 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2015 | 49 | 0.030 |
Why?
|
| Chemokine CCL2 | 2 | 2007 | 61 | 0.030 |
Why?
|
| Influenza A Virus, H1N2 Subtype | 1 | 2015 | 6 | 0.030 |
Why?
|
| Point Mutation | 1 | 2015 | 169 | 0.030 |
Why?
|
| Nucleoproteins | 1 | 2015 | 32 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2015 | 49 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2015 | 124 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2015 | 111 | 0.030 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1995 | 42 | 0.030 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2015 | 103 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1569 | 0.030 |
Why?
|
| Tripartite Motif Proteins | 1 | 2014 | 42 | 0.030 |
Why?
|
| Receptors, Complement 3b | 1 | 2014 | 12 | 0.030 |
Why?
|
| Genetic Drift | 1 | 2014 | 15 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 240 | 0.030 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2014 | 98 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2014 | 127 | 0.020 |
Why?
|
| Models, Biological | 1 | 2019 | 1193 | 0.020 |
Why?
|
| HIV Infections | 1 | 2020 | 961 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 316 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 238 | 0.020 |
Why?
|
| Genotype | 1 | 2015 | 676 | 0.020 |
Why?
|
| Computational Biology | 1 | 2015 | 369 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2014 | 579 | 0.020 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2014 | 263 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2014 | 423 | 0.020 |
Why?
|
| Paneth Cells | 1 | 2011 | 6 | 0.020 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2011 | 23 | 0.020 |
Why?
|
| Duodenum | 1 | 2011 | 41 | 0.020 |
Why?
|
| Gliotoxin | 1 | 2011 | 5 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 1573 | 0.020 |
Why?
|
| Inflammasomes | 1 | 2014 | 352 | 0.020 |
Why?
|
| Streptococcus pneumoniae | 1 | 2010 | 67 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2014 | 719 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 899 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 588 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 1995 | 789 | 0.020 |
Why?
|
| Metalloendopeptidases | 1 | 2009 | 20 | 0.020 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2009 | 29 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2010 | 257 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 5681 | 0.020 |
Why?
|
| DNA-Cytosine Methylases | 1 | 2008 | 3 | 0.020 |
Why?
|
| Mannose-Binding Lectins | 1 | 2008 | 21 | 0.020 |
Why?
|
| Cell Compartmentation | 1 | 2008 | 34 | 0.020 |
Why?
|
| Hybridomas | 1 | 2008 | 63 | 0.020 |
Why?
|
| Intracellular Space | 1 | 2008 | 33 | 0.020 |
Why?
|
| United States | 1 | 2021 | 8186 | 0.020 |
Why?
|
| Endonucleases | 1 | 2008 | 84 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2008 | 180 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 170 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2011 | 718 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 2007 | 154 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2009 | 428 | 0.020 |
Why?
|
| Herpesvirus 2, Human | 1 | 2005 | 14 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2007 | 755 | 0.010 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2004 | 351 | 0.010 |
Why?
|
| Age Factors | 1 | 2005 | 1595 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2005 | 1438 | 0.010 |
Why?
|
| Glycogen Synthase | 1 | 1995 | 4 | 0.010 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 1995 | 10 | 0.010 |
Why?
|
| Protein Phosphatase 1 | 1 | 1995 | 19 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1995 | 152 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1995 | 165 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1995 | 129 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1995 | 514 | 0.010 |
Why?
|
| Biopsy | 1 | 1995 | 463 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1995 | 1980 | 0.010 |
Why?
|